跳至主要内容
临床试验/IRCT20150724023315N2
IRCT20150724023315N2招募中3 期

Evaluation of the effect of melatonin on improving the symptoms of patients with COVID-19-double-blind randomized clinical trial

Birjand University of Medical Sciences0 个研究点目标入组 46 人开始时间: 待定最近更新:
适应症

试验速览

阶段
3 期
状态
招募中
入组人数
46

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 years 至 75 years(—)
性别
All

入选标准

  • Age 18 to 75 years
  • Diagnosis of COVID-19 in the last 24 hours
  • One of the three following: respiratory rate more than 30 per minutes, o2 saturation less than or equal to 93% at room temperature, PaO2/FiO2 less than or equal to 300
  • Female patients should not be pregnant and should not become pregnant until 30 days after the end of the study

排除标准

  • Patients with shock or hemodynamic instability (increase or decrease in blood pressure and irregular heartbeat)
  • GFR less than 30 ml/minute
  • History of cirrhosis, hepatitis and severe liver diseases
  • History of hypertension, depression (taking fluvoxamine and other potent CYP1A2 inhibitors) and epilepsy
  • Patients with a history of allergic reaction or allergy to melatonin
  • Patients receiving chemotherapy for cancer
  • Severe diseases of the immune system
  • Pregnant and lactating women
  • Use of alcohol and benzodiazepines

研究者

相似试验